Drospirenone; Estradiol Patent Expiration
Drospirenone; Estradiol was first introduced by Bayer Healthcare Pharmaceuticals Inc
Drospirenone; Estradiol Patents
Given below is the list of patents protecting Drospirenone; Estradiol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Angeliq | US8906890 | Very low-dosed solid oral dosage forms for HRT | Oct 22, 2031 | Bayer Hlthcare |
| Angeliq | US6933395 | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
Aug 11, 2017
(Expired) | Bayer Hlthcare |
Drospirenone; Estradiol's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List